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predictive variables, respectively directly and inversely related to CFRD develop-
ment (pseudo R2 for the model: 0.581, p< 0.001). Glycated hemoglobin and base-
line glucose concentrations were directly related with outcome at univariate analysis
whereas c-peptide concentrations were inversely related. In contrast, no relationship
emerged between insulin-sensitivity indexes and outcome. Anthropometric (weight,
height z scores, BMI) and pulmonary function indexes were also unrelated.
Conclusions: Defects in insulin secretion are determinants of subsequent CFRD
development. The evaluation of insulin concentrations during OGTT may be helpful
in CFRD prediction.
This study has been supported by a grant of Fondazione per la Ricerca sulla Fibrosi
Cistica ONLUS – Verona (Progetto FFC 16/2005).
*This Poster has been presented also as Oral Communication, by invitation of
the Scientiﬁc Committee
P59 CONTINUOUS SUBCUTANEOUS GLUCOSE MONITORING IN
CYSTIC FIBROSIS (CF) PATIENTS
F. Patriarchi, A. Menichella, F. Costantino, R. Scrocca, S. Bertasi, S. Quattrucci.
Cystic Fibrosis Center, Department of Pediatrics, “Sapienza” University of Rome,
Italy
Objectives:
1. To study the effectiveness and reliability of the continuous monitoring of blood
glucose (CGMS) in CF patients, to be able to identify at an early stage any
condition of glycemic intolerance (IGT) or even diabetes.
2. To evaluate if the pre-diabetic treatment with insulin may lead to an improvement
of CF pts glyco-metabolic control and of other clinical parameters such as BMI
and FEV1.
Materials and Methods: We evaluated 10 CF pts (5 M and 5 F) with standard
OGTT or altered baseline glycemic values. These pts had also shown a decrease in
FEV1 and BMI values during the 2 years before the beginning of the study.
A microdialysis ﬁber was inserted subcutaneously into the periumbelical region
and perfused with a buffer solution. Glucose concentrations in the dialysate were
measured every 3 minutes by the glucose sensor over a 48-h period, during which
6 capillary blood samples were also collected before and after the 3 mean meals to
evaluate the correlation between CGMS and traditional methods. The pts diagnosed
for Cystic Fibrosis Related Diabetes (CFRD) as a result of monitoring, began
insulinic therapy. After a follow-up period of 14 months glycaemia, FEV1 and
BMI were evaluated again for each of them.
Results: Both the insertion of the ﬁber and the wearing of the device were well
tolerated by the pts. Subcutaneous glucose levels were well correlated with capillary
glucose measurements (r = 0.88, P< 0.001) over a wide range (45–250mg/dl) for
up to 48 h. An analysis of 120 relevations showed a linear relationship between
the CGMS and serial capillary blood glucose levels, and 98.33% of the data fell
in the A and B regions of the error grid analysis. The results of CGMS for 48
hours conﬁrmed the presence of IGT in all pts and identiﬁed early CFRD in 6 pts
who had glycemic peaks > 200mg/dl. After they were given insulinic therapy they
showed an improvement of the glyco-metabolic control and an increasement of 6%
of BMI values during the 14 months of follow up. FEV1% values were unchanged.
Conclusions: The CGMS demonstrated high reliability and provided much more
informations about glycemic excursions and glucose trends than the traditional
diagnostic methods, making it possible to identify earlier the CFRD in CF pts and
begin as soon as possible an individual insulinic treatment.
P60 EXCEPTIONALLY EARLY OCCURRENCE OF EBV RELATED
LYMPHOMA AFTER LUNG TRANSPLANTATION
V. D’Alu`, M. Rolla, A. Menichella, F. Patriarchi, L. Locorriere, C. Scacchi,
D. Russo, P. Troiani, S. Quattrucci. Cystic Fibrosis Center, Department of
Pediatrics, “Sapienza” University of Rome, Italy
We basically describe the case of a CF pt that developed fatal EBV related
lymphoma 4 months after lung transplantation. A 17 years old female CF pt
underwent bilateral sequential lung transplantation uneventful in May 2006. All
other recipients from the same multi-organ donor are currently alive and well
with no evidence of lymphoproliferative disease. Standard immunosuppression was
instituted with Tacrolimus, Azathioprine and Prednisone. In October 2006 the pt
was readmitted to the hospital with a decrease of FEV1 of > 10%, increased
inﬂammation index, anemia, low platelets count, fever (39−40º). Chest x-ray and
CT showed diffused peribronchial inﬁltrates. Physical and abdominal examination
was negative; abdominal echography was also negative. Wide spectrum antibiotics
were administered. Bacteriology, virology and fungal exams were performed, but
all proved negative, including the search for EBV and CMV. Still, high fever
(39−40º) persisted along with lymphocytosis and neutropenia. With the suspect
of CMV infection Ganciclovir (10mg/kg/die IV) and immunoglobulins were
administered. Immunosuppression was discontinued. Ten days after admission,
without any clinical improvement, the spleen became palpable and a laterocervical
lymphonodus evident. A biopsy was immediately performed; abdominal echography
and CT were also performed. Multiple lymphadenopaties were revealed, along with
hepatosplenomegaly and moderate pleural effusion. EBV related lymphoma was
suspected on the basis of these ﬁndings and Retuximab therapy was started. The
clinical setting deteriorated over the following days and multiple organ failure
developed. The patient died on the 18th day after admission.
Necropsy conﬁrmed clinical ﬁndings, and in situ hybridization conﬁrmed the
expression of EBV genome in over 90% of the large B Lymphoma cells.
We believe it is important to be aware that Lymphoma can develop also in the early
postoperative period after lung transplantation. Although it is common knowledge
that lymphoproliferative disease can occur in as much as 10% of lung transplanted
patients, this usually occurs years after the transplant. The early occurrence of this
dramatic complication certainly entails exceptional severity and difﬁcult diagnostic
problems, which might be facilitated by its awareness.
P61 TOTIRESISTENT BURKHOLDERIA CEPACIA COMPLEX SEPSIS
IN A 62-YEAR-OLD WOMAN WITH CYSTIC FIBROSIS
A. Antonelli, I. Balteri, A. Schreiber, B. Grosso, B. Messore, V. De Rose. Centro
Regionale per la Fibrosi Cistica Piemonte e Valle d’Aosta – Settore Adulti; Clinica
di Malattie dell’Apparato Respiratorio – Universita` degli Studi di Torino; Azienda
Ospedaliera San Luigi Gonzaga, Orbassano, Torino, Italy
Colonization of cystic ﬁbrosis (CF) airways with Burkolderia cepacia complex
(Bcc) is associated with an accelerated pulmonary deterioration and increased
mortality. Bcc sepsis is one of the most dramatic events that can occur in a patient
chronically infected.
We describe the case of a 62-year-old woman with CF (diagnosed at the age of
50), with type II chronic respiratory insufﬁciency in long term oxygen therapy and
nocturnal non-invasive ventilation, severe obstructive respiratory impairment (FEV1
29% of the predicted value), totiresistant B. cenocepacia (genomovar III) chronic
pulmonary infection. On July 2007 she presented with obnubilation, worsened gen-
eral and respiratory conditions and pyrexia; blood culture detected Bcc septicaemia.
The organism was resistant to all antibiotics singly and synergically in vitro tested,
and the sepsis occurred while she was being treated with intravenous ceftazidim
and oral co-trimoxazole.
Multiple antibiotics, including levoﬂoxacin per os, ceftazidim i.v., meropenem as
continuous intravenous infusion associated with high-dose i.v. methylprednisolone
were administered.
Despite the fact that Bcc was resistant to all tested antibiotics, her clinical conditions
progressively improved and she overcame the acute Bcc sepsis.
The exact mortality rate associated with Bcc septicaemia in CF patients is not
known, but it is thought to approach 100%.
We speculate that the intensive antibacterial therapy, in particular the continuous
intravenous infusion of meropenem, and the anti-inﬂammatory effects of high-dose
corticosteroids, could signiﬁcantly contribute to the survival of the patient.
Moreover, the favourable outcome of this case highlights that the resistance to
antibiotics detected in vitro does not always correspond to clinical inefﬁcacy.
P62 FUNCTIONAL ENDOSCOPIC SINUS SURGERY (FESS) IN
PATIENTS WITH CYSTIC FIBROSIS (CF)
C. Scacchi, L. Locorriere, V. Savastano, F. Zardo, D. Russo, S. Bertasi. Cystic
Fibrosis Center, Department of Pediatrics, “Sapienza” University of Rome, Italy
Objective: To determine the effectiveness of FESS through the reduction of
symptoms and the improvement of related clinical parameters in children and young
adults with CF and sinonasal disease (SND).
Materials and methods: 12 children and young adults (15 years median age;
range 7–38) with medically refractory SND were examined before and after FESS.
The main outcome measures were sinonasal symptoms, spirometric values (forced
expiratory volume in 1 second, FEV1, and peak expiratory ﬂux, PEF), and number
of hospitalizations. The extent of polyposis was graded endoscopically and on
computer tomography images. The sinonasal symptoms were inquired through a
questionnaire pre- and postoperatively.
Results: The mean follow up time after surgery was 15.1 months. Postoperatively,
polyp recurrence was seen in 5 pts of 12. Before surgery, bilateral nasal polyposis
was an endoscopic ﬁnding in 11 pts of 12, and 50% of them had polyps occluding
the middle meatus (grade 2 polyposis). 4 pts had undergone previous polypectomy
in other centers. The symptoms complained were nasal obstruction (100%), nasal
discharge and postnasal drip (67%) and anosmy (50%). Only 2 pts complained
headache. After FESS, 4 pts reported no nasal obstruction and marked decline in
the frequency of nasal discharge and postnasal drip (25%). Headache shows no
improvement.
Spirometric values and the number of pulmonary exacerbations were found to be
related to the severity degree of lung disease. On the basis of these observations CF
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pts could be divided into two groups according to spirometric values before FESS
(FEV1>70%, mild pulmonary disease, n=7 and FEV1<70%, moderate and severe
pulmonary disease, n=5). One year after FESS, spirometry was unchanged in all
the pts with FEV1>70% with a PEF increase in 2 subjects, while spirometry was
decreased in patients with FEV1<70%, depending on worsening of the pulmonary
status. 1 subject had PEF increase. After FESS the number of hospitalizations in
patients with FEV1>70% was similar to the value observed in the previous year in
the majority of subjects (n=5) or was reduced (n=2) while it was increased in all
the pts with FEV1<70%.
Conclusions: FESS was effective and provided signiﬁcant SND associated symp-
toms relief, with an improvement of the quality of life, despite the possibility of
recurrence. A larger number of pts and a longer follow up period are needed to
evaluate the long term effects of FESS on pulmonary function and to study the
recurrence rate.
P63 CLOSTRIDIUM DIFFICILE (CD) COLITIS IN A CF LUNG
TRANSPLANTED PATIENT
A. Menichella, M. Rolla, P. Troiani, F. Patriarchi, S. Quattrucci. Cystic Fibrosis
Center, Department of Pediatrics, “Sapienza” University of Rome, Italy
CD infection is a rare though often fatal complication after lung transplantation. In
addition, Sirolimus is deemed to increase infections hazard in these patients.
We basely describe the case of one such patient who was cured thanks to timely
diagnosis and appropriate treatment.
A 39-year-old male CF patient underwent Bilateral Sequential Lung Transplantation
in May 2006. In June 2007 Sirolimus was inclosed in the immunosuppressive
regimen for renal failure.
In July 2007, 3 weeks later, the patient presented with diarrhea, high septic fever
(40º) and abdominal pain. Laboratory tests for inﬂammation were markedly in-
creased and abdominal echography revealed thickening of intestinal walls (20mm);
this ﬁnding was conﬁrmed by MR. Massive ascitis was also present.
Because of the history of Sirolimus administration and the clinical patterns a
diagnosis of CD colitis was suspected and the appropriate therapy was instituted.
Sirolimus was discontinued; 5 Toramix aferesis were performed; Metronidazole
(500mg q6h.) and Meropenem (50mg/kg/die) were administered and support
therapy (blood and plasma transfusion, albumin, total parental nutrition) was started.
The patient moderately improved until positive diagnosis of CD infection was
obtained by stool culture. At this point high dose steroids (1mg/kg per day) were
started. The patient progressively improved and inﬂammation indexes normalized
within 10 days. The patient was discharged asymptomatic 3 weeks after admission
and MR demonstrated reduction of bowel thickness from 20mm to 10mm. The
patient has been in excellent health since then.
In conclusion, if clinically compatible, in patients treated with Sirolimus, a diagnosis
of CD should be suspected and timely treated.
P64 LONG TERM FOLLOW-UP OF A CYSTIC FIBROSIS (CF) PATIENT
WITH PREVIOUS NEUROBLASTOMA
R. Casciaro, M. Haupt, S. Pessano, M. Caso, L. Bergamino, L. Minicucci,
R. Lorini. Department of Pediatrics – CF Centre, G. Gaslini Institute, Genova,
Italy
Herein we report the case of L.D.M. a 16-year-old female affected by CF diagnosed
at two months of life by evocative symptoms and conﬁrmed by positive sweat test;
genotype M1V / del-17a, 17b, 18. Stage 3 neuroblastoma of the right adrenal
gland was diagnosed at the age of 22 months. She received antiblastic therapy
for 4 months following AIEOP NB92 protocol, without a signiﬁcant reduction of
the tumour. AIEOP NB92 protocol was followed by surgical therapy and removal
of 70% of the neoplastic mass. The patient was off therapy after four metabolic
radiotherapeutic cycles with MIBG. At 4 years of age she developed iatrogenic
hypothyroidism treated with thyroxin. At 12 years of age hepatic nodular hyperplasia
was demostrated by abdominal US tomography and conﬁrmed by high resolution
CT (HRCT).
The neuroblastoma and the subsequent therapy did not show any side effects on
the pulmonary function of our patient: chronic colonization by oxacillin susceptible
Staphylococcus aureus, only one sputum positive for Pseudomonas Aeruginosa (in
1993 during immunosuppressive therapy). FEV1 70% of predicted values. Moreover
she maintained an optimal nutritional status (BMI 22.89).
From January to May 2007 three episodes of abdominal pain with icterus, hyper-
transaminasemia and hyperbilirubinemia were reported. Abdominal US tomography
showed only microcholelithiasis, while HRCT showed an increased number and
volume of the hepatic lesions. Normal serum and urinary tumor markers level
(NSE, CA19.9, CEA, VMA and HVA).
MIBG scintigraphy showed accumulated metaiodobenzylguanidine in midline epi-
gastric region. PET scintigraphy ruled out an active disease. These results conﬁrmed
the diagnosis of focal nodular hepatic hyperplasia. No variation was found in the
residual retroperitoneal mass volume (84x67x72mm).
We underline this case of a Cystic Fibrosis patient with previous neuroblastoma
because such a long term follow up (14 years) in a neuroblastoma with a stable
retroperitoneal remaining tumour is so uncommon to be reported.
A multidisciplinary approach was necessary in the differential diagnosis of the
hepatic symptoms because of the coexistence of these two complex pathologies.
P65 LUNG EXACERBATION IN A CYSTIC FIBROSIS (CF)
PATIENT CAUSED BY A MULTIRESISTANT EXTENDED
SPECTRUM b-LACTAMASE (ESBL) PRODUCING STRAIN OF
ESCHERICHIA COLI (EC)
M. Caso1, R. Casciaro1, S. Pessano1, L. Ambrosini1, G. Manno2, M. Mentasti2,
P. Morelli2, L. Minicucci1, R. Lorini1. 1Department of Pediatrics – CF Centre;
2General Laboratory of Analysis, G. Gaslini Institute, Genova, Italy
ESBL have the ability to hydrolyse cephalosporins and monobactams, but not
cephamycins or carbapenems. The majority of ESBL-producing organisms have
been reported from hospitalized patients in Intensive Care Units (ICU).
Our experience is about a 47-year-old female pt affected by CF (DF508/DF508),
chronically colonized by mucoid Pseudomonas aeruginosa (PAM) since 1988, in
stable clinical and respiratory conditions (FEV1 40%) until 2005. Her clinical course
was characterized by several lung exacerbations and need for O2 therapy since 2006
and “Non-Invasive Ventilation” since March 2007.
In May 2007, during lung exacerbation treated with iv colistin, amikacin and
ceftazidime, worsening of clinical conditions with severe hypercapnia and acidosis
(pH 7.28; pCO2 88mmHg; HCO−3 35mmol/l) was found and the pt was admitted
in ICU. After one week in ICU, because of clinical improvement (pH 7.368;
pCO2 70.9mmHg; HCO
−
3 39.9mmol/l), the pt was readmitted at the CF center
where started i.v. therapy with ceftazidime, amikacin and ciproﬂoxacin for 3
wks. After a new dramatic worsening of clinical conditions characterized by
fever and dyspnea, a multiresistant ESBL producing strain of EC (106 cfu/ml)
was isolated from sputum. Its antibiotic susceptibility, assessed by disc-diffusion
in Mueller Hinton Agar showed sensibility only to meropenem and fosfomicin
among the 16 tested antibiotics (amikacin, amoxicillin/clavulanate, ampicillin,
aztreonam, cefepime, cefotaxim, cefoxitin, ceftazidime, cefuroxime, ciproﬂoxacin,
fosfomycin, levoﬂoxacin, meropenem, piperacillin/tazobactam, tobramycin and
trimethoprim/sulfametoxazole). ESBL production was conﬁrmed according to CLSI
guidelines. The patient was isolated and changed iv therapy, starting meropenem,
fosfomycin and amikacin, which was performed for 15 days. The patient showed an
immediate clinical improvement and there was a progressive ESBL load reduction
in the sputa, with a simultaneous increase of PAM load to 106 cfu/ml. During
the treatment for EC infection all blood culture taken resulted negative. Although
Enterobacteriaceae are not speciﬁc pathogens in CF, our experience shows that
it’s important to search them in the sputum and to treat. A prompt and speciﬁc
therapy succeeded in eradicating EC ESBL. Collaboration between CF centre and
microbiologists is highlighted!
P66 POSITIVE LUNG I-131 WHOLE SCAN IN A THYROIDECTOMIZED
CYSTIC FIBROSIS PATIENT FOR THYROID CANCER: CYSTIC
FIBROSIS PULMONARY INVOLVEMENT OR THYROID
METASTASIS?
M. Zanardelli, G. Pizzamiglio, M.A. Monti, N. Gervasini, F. Blasi. Adult Cystic
Fibrosis Center, Bronchopneumology Unit, Ospedale Maggiore Policlinico,
Mangiagalli e Regina Elena, Milan, Italy
Cystic ﬁbrosis (CF) is a chronic hereditary disease with increasing life expectancy
(36.5 years) due to the improvement in patient treatment and assistance. As the CF
population is getting older the incidence of degenerative and malignant diseases is
increasing. We describe a case of thyroid cancer in a female CF 47-year-old patient,
who underwent total thyroidectomy and radioiodine ablation with a positive iodine-
131 uptake in the left lung. In this patient the diffuse pulmonary involvement made
the differential diagnosis between primitive CF disease or metastastic illness difﬁ-
cult. The patient, whose CF diagnosis was performed at the age of 32, presented se-
vere pulmonary involvement and chronic Pseudomonas aeuruginosa infection. Dur-
ing the admission to our CF Adult Centre for a high-dose antibiotic therapy because
of pulmonary exacerbation, a nodular lesion at the right thyroid lobe was detected.
The neck US-scan showed features typical for malignancy without lymph nodal
involvement. Fine needle aspiration of the lesion was positive for papillary thyroid
cancer. The patient, after a high-dose antibiotic IV therapy, underwent total thy-
roidectomy and right lymphadenectomy without surgical nor respiratory complica-
tions. The I-131 whole-body scan, performed after radioiodine ablation of post sur-
gical thyroid remnants, showed two areas of focal I-131 uptake in the left lung. Her
serum thyroglobulin (TG) level and antithyroglobulin antibodies below detection
